Chemoprevention of gastric cancer development after Helicobacter pylori eradication therapy in an East Asian population: Meta-analysis

Table 1 Characteristics of the studies

Ref.	Country	Primary or metachronous cancer	Design	Disease at basement	Follow-up periods (yr)	Patients number	Age (yr)	Sex (male/ female)	Regimen of eradication therapy	Eradication rate (%)
Fukase et al[31], 2006	Japan	Metachronous	RCT	Gastric cancer	3	544	68 (62-73)	386/119	LPZ(30)/AMPC(750)/CAM(200), BID, 7D	75.0
Choi et al[32], 2018	South Korea	Metachronous	RCT	Gastric cancer	5.9	396	59	298/104	RPZ(10)/AMPC(1000)/CAM(500), BID 7D	80.4
Choi et al[33,69]	South Korea	Metachronous	RCT	Gastric cancer	6	898	60.4	594/283	OPZ(20)/AMPC(1000)/CAM(500), BID 7D	82.6
Uemura et al[70], 1997	Japan	Metachronous	Cohort	Gastric cancer	3	132	69 (44-85)	97/35	1st: OPZ(20)/CAM(400) 14D, 2nd: OPZ(20)/AMPC(1500)/MNZ(500), BID 14D	46.2
Nakagawa et al[71], 2006	Japan	Metachronous	Cohort	Gastric cancer	2	2825	NA	NA	NA	NA
Shiotani et al[72], 2008	Japan	Metachronous	Cohort	Gastric cancer	2.75	100	69	67/13	PPI/AMPC(750)/CAM(200), BID 7D	81.3
Han et al[73], 2011	South Korea	Metachronous	Cohort	Gastric cancer	2.7	176	61.8 (43-83)	112/64	NA	NA
Kim et al[74], 2011	South Korea	Metachronous	Cohort	Gastric cancer	5.1	55	60.7 (43-81)	36/19	NA	50.9
Maehata et al[75], 2012	Japan	Metachronous	Cohort	Gastric cancer	3	268	69 (49-90)	194/74	PPI/AMPC(750)/CAM(200), BID 7D	78.2
Seo et al[76], 2013	South Korea	Metachronous	Cohort	Gastric cancer	2.27	74	62	55/19	PPI/AMPC(1000)/CAM(500), BID 7-14D	82.4
Kato et al[77], 2013	Japan	Metachronous	Cohort	Gastric cancer	2.23	368	70.5	953/305	NA	NA
Bae et al[78], 2014	South Korea	Metachronous	Cohort	Gastric cancer	5	1007	63 (28-88)	785/222	PPI/AMPC(750)/CAM(200), BID 7-14D	NA
Kim et al[79], 2014	South Korea	Metachronous	Cohort	Gastric cancer	4.3	374	64 (35-87)	278/96	PPI/AMPC(1000)/CAM(500), BID 7D	72.1
Kwon et al[80], 2014	South Korea	Metachronous	Cohort	Gastric cancer	3.4	283	59	190/93	PPI/AMPC(750)/CAM(200), BID 7D	68.9
Jung et al[27], 2015	South Korea	Metachronous	Cohort	Gastric cancer	3.36	1041	62.7	773/268	LPZ(30)/AMPC(1000)/CAM(500), BID 7-14D	NA
Lim et al[28], 2015	South Korea	Metachronous	Cohort	Gastric cancer	3.1	933	63.0 ± 9.51	512/250	NA	NA
Kim et al[81], 2016	Korea	Metachronous	Cohort	Gastric cancer	2.5	257	67	189/68	PPI/AMPC(1000)/CAM(500), BID 7D	86.3
Ami et al[82], 2017	Japan	Metachronous	Cohort	Gastric cancer	4.47	438	69.4 ± 8.7	421/118	LPZ(30) or RPZ(10)/AMPC(750)/CAM(200), BID 7-14D	NA
Kwon et al[29], 2017	South Korea	Metachronous	Cohort	Gastric cancer	3.725	590	63	398/192	RPZ(20)/AMPC(1000)/CAM(500), BID 7D	81.8
Chung et al[30], 2017	South Korea	Metachronous	Cohort	Gastric cancer	5.125	185	67.4 (45-87)	141/44	PPI/AMPC/CAM, BID 7D	NA
Han et al[83], 2018	South Korea	Metachronous	Cohort	Gastric cancer	5	565	61	440/125	NA	NA
Cho et al[17], 2013	South Korea	Metachronous	RCT	Gastric cancer	3	169	56	117/52	RPZ(10)/AMPC(1000)/CAM(500), BID 7D	77
Wong et al[18], 2004	China	Primary	RCT	Gastritis alone	7.5	1630	42.2 (35-65)	880/750	OPZ(20)/AMPC(750)/MNZ(400), BID 14D	82.5
Ma et al[23], You et al[84] and Li et al[85]	China	Primary	RCT	Non-gastric cancer	14.3	2258	47.1	1808/1603	OPZ(20)/AMPC(1000), BID 7D	66.2
Wong et al[19], 2012	China	Primary	RCT	With/without metaplasia	2	1024	53.0 (35-64)	473/551	PPI/AMCP(1000)/CAM(500), BID 7D	71.3
Zhou et al[24], 2014, Leung et al[86], 2004	China	Primary	RCT	Non-gastric cancer	10	554	53.35 ± 8.49	268/284	OPZ(20)/AMPC(1000)/CAM(500), BID 7D	88.9
Saito et al[22], 2000	Japan	Primary	Cohort	Gastric adenoma	2	64	79.2 (68-92)	35/29	OPZ(20)/AMCP(1000)/CAM(400), BID 7D	75
Uemura et al[52], 2001	Japan	Primary	Cohort	With/without PU	7.7	1526	52.4	869/657	NA	NA
Kato et al[87], 2006	Japan	Primary	Cohort	With/without PU	5.9-7.7	3021	54	1868/1153	LPZ(30)/AMPC(750)/CAM(200), BID 7-14D	NA
Takenaka et al[88], 2007	Japan	Primary	Cohort	With/without PU	3.17	1807	53.6 ± 12.4	1289/518	Dual therapy or PPI/AMPC(750)/CAM(200 or 400), BID 7D	82.9
Ogura et al[89], 2008	Japan	Primary	Cohort	With/without PU	3.2	708	62	400/308	LPZ(30)/AMPC(750/1000)/CAM(400) or MNZ(250), BID 7D	74
Kim et al[90], 2008	South Korea	Primary	Cohort	With/without PU	9.4	1790	46.7	1483/297	Tripotassi-um dicitrate bismuthate (300, QID)/MNZ(500, TID)/TC(500, QID), 5D or OPZ(20)/CAM(500)/AMPC(1000)BID 7D	NA
Mabe et al[53], 2009	Japan	Primary	Cohort	With/without PU	5.6	4133	52.9 (13-91)	2964/1169	LPZ(30) or OPZ(20)/AMPC(750)/CAM(200 or 400), BID 7D	64.8
Yanaoka et al[25], 2009	Japan	Primary	Cohort	Non-gastric cancer	9.3	4129	49.8	5560/107	OPZ(20)/AMPC(750 or 500), BID 14D, OPZ(20)/AMPC(750)/CAM(200), BID 7D	87.2
Watanabe et al[26], 2012	Japan	Primary	Cohort	Non-gastric cancer	5.4	823	NA	NA	OPZ(20, BID)/AMPC(750 or 500, BID) 14D or OPZ(20)/AMPC(750)/CAM(200), BID 7D	82.0
Lee et al[20], 2013	China	Primary	Cohort	With/without PU or dysplaisa	5	8242	49.2 ± 12.8	1888/2233	PPI/AMCP(1000)/CAM(500), BID 7D	78.7
Shichijo et al[21], 2015	Japan	Primary	Cohort	Intestinal metaplasia	6.7 ± 4.7	659	60.1 ± 11.0	374/355	LPZ(30)/AMPC(750 or 1000)/CAM(200) or MNZ(250), BID 7D	NA
Take et al[91-94]	Japan	Primary	Cohort	Peptic ulcer	9.9	1222	49.9 ± 8.3	1087/135	Dual or Triple therapy	NA

Non-gastric cancer: patients had no history of gastric cancer, but were unknown to have peptic ulcer and dysplasia. AMPC: Amoxicillin; BID: Twice-daily dosing; CAM: Clarithromycin; D: Day; LPZ: Lansoprazole; MNZ: Metronidazole; NA: Not available; OPZ: Omeprazole; PPI: Proton pump inhibitor; PU: Peptic ulcer; QID: Four-times daily dosing; RCT: Randomized control trial; RPZ: Rabeprazole; TID: Three-times daily dosing; TC: Tetracycline.